Array BioPharma Inc.
Array BioPharma Reports Positive Results of Its Oral Glucokinase Activator in Type 2 Diabetes Patients
Published in Drug Week, August 28th, 2009
ARRY-403 was evaluated in a Phase 1 single ascending dose study. The study included seven dose cohorts, with a total of 41 patients with Type 2 diabetes receiving either placebo or single doses of ARRY-403 ranging from 25 mg to 400 mg. ARRY-403 was well tolerated at all doses. ARRY-403 was rapidly absorbed, and exposure was dose-dependent. The pharmacokinetic profile is...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2009-08-28)
More Articles from Drug Week
- Alcoholism
A synthetic derivative of the kudzu vine can reduce drinking and prevent relapse - American Association for Cancer Research
Budesonide is not beneficial for the treatment of diarrhea in metastatic melanoma patients - American Dietetic Association
ADA publishes practice guidelines for nutrition care for patients with spinal cord injury - American Thoracic Society
Misuse of common antibiotic is creating resistant TB - JAMA and Archives Journals
Aspirin use after colorectal cancer diagnosis associated with improved survival - Johns Hopkins University Bloomberg School of Public Health
Guided care reduces cost of health care for older persons with chronic conditions - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
